Safety, Pharmacokinetics and Biological Activity of Enlimomab (Anti-ICAM-1 Antibody): An Open-Label, Dose Escalation Study in Patients Hospitalized for Acute Stroke

Publisher: Karger

E-ISSN: 1421-9913|40|2|78-83

ISSN: 0014-3022

Source: European Neurology, Vol.40, Iss.2, 1998-08, pp. : 78-83

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content